Bio-Rad Laboratories, Inc. Class B (BIO.B) Dividend History

Bio-Rad Laboratories, Inc. Class B (BIO.B) is a global leader in life science research and clinical diagnostics. The company develops, manufactures, and sells a broad range of products and systems used in scientific research, healthcare, and clinical testing laboratories. Known for its innovative solutions in areas such as genomics, proteomics, and immunoassays, Bio-Rad supports advancements in scientific discovery and patient care.

Dividend History

Bio-Rad Laboratories, Inc. Class B currently does not pay dividends

Company News

Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment

The global molecular diagnostics for infectious disease market is poised for growth, driven by advancements in biotechnology and genomics, as well as the impact of multiplex assays on diagnosis and treatment. The report covers dynamic trends, including pathogen evolution, globalization, and climate change impacts, and provides insights on the U.S. Medicare Fee Schedules and global data.

GlobeNewswire Inc.

Featured Companies: A ABT BDX BIO DHR HOLX QDEL QGEN TMO
Epigenetics Market Anticipated to Achieve 11.8% CAGR

The global epigenetics market is projected to grow from $4.8 billion in 2024 to $8.5 billion by 2029, driven by factors like rising cancer rates, technological advances, and the trend towards precision medicine.

GlobeNewswire Inc.

Featured Companies: BIO BMY EXAS GH HOLX
Antibody and Protein Labeling Kits Market Outlook, Trends, Growth and Opportunities | Exactitude Consultancy

The global antibody and protein labeling kits market is projected to grow significantly over the next decade, driven by the expanding landscape of biomedical research, diagnostic advancements, and pharmaceutical innovations. The market is expected to increase from approximately USD 685 million in 2024 to over USD 1.56 billion by 2034, registering a CAGR of 8.7%.

GlobeNewswire Inc.

Featured Companies: BIO TMO
Tissue Diagnostics Market to Reach $12.4 Billion by 2029, Growing at 7.0% CAGR

The global tissue diagnostics market is projected to grow from $8.3 billion in 2023 to $12.4 billion in 2029 at a CAGR of 7.0%, driven by the increasing incidence of cancer, the importance of early cancer testing, and the aging population. The report covers key market segments, trends, and leading companies in this space.

GlobeNewswire Inc.

Featured Companies: A ABT BDX BIO DHR ILMN MYGN PHG QGEN TMO
Global Immunodiagnostics Market to Cross the USD 32 Billion by 2032 | DelveInsight

The global immunodiagnostics market is expected to grow significantly, driven by the rising prevalence of chronic and infectious diseases, the increasing need for point-of-care testing, and the surge in product launches.

GlobeNewswire Inc.

Featured Companies: ABT BDX BIO DGX DHR QDEL TMO

Dividend data last updated 06/07/2025 14:39:25 UTC